Virtu KCG Holdings LLC grew its position in shares of Astrazeneca PLC (NYSE:AZN) by 10.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,823 shares of the company’s stock after purchasing an additional 3,388 shares during the period. Virtu KCG Holdings LLC’s holdings in Astrazeneca PLC were worth $1,187,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in AZN. Meeder Asset Management Inc. acquired a new stake in shares of Astrazeneca PLC during the 2nd quarter worth about $105,000. Salem Investment Counselors Inc. acquired a new stake in shares of Astrazeneca PLC during the 1st quarter worth about $107,000. Tower Research Capital LLC TRC boosted its stake in shares of Astrazeneca PLC by 3,782.0% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after purchasing an additional 3,782 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Astrazeneca PLC by 27.1% during the 1st quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after purchasing an additional 964 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. boosted its stake in shares of Astrazeneca PLC by 71.2% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after purchasing an additional 1,769 shares during the last quarter. 14.17% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/virtu-kcg-holdings-llc-has-1-19-million-holdings-in-astrazeneca-plc-azn/1600653.html.

Shares of Astrazeneca PLC (AZN) opened at 33.88 on Friday. The stock has a market cap of $85.78 billion, a price-to-earnings ratio of 22.22 and a beta of 0.74. The stock’s 50 day moving average is $30.33 and its 200-day moving average is $31.81. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60.

Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The firm’s quarterly revenue was down 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.83 EPS. On average, analysts anticipate that Astrazeneca PLC will post $1.91 EPS for the current year.

The company also recently declared a None dividend, which was paid on Monday, September 11th. Investors of record on Friday, August 11th were paid a $0.44 dividend. The ex-dividend date of this dividend was Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s payout ratio is 44.92%.

AZN has been the topic of several research analyst reports. Piper Jaffray Companies reissued a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. BidaskClub cut shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. BMO Capital Markets initiated coverage on shares of Astrazeneca PLC in a research report on Wednesday, September 6th. They issued an “outperform” rating and a $38.00 target price on the stock. Cowen and Company reissued a “hold” rating and issued a $34.00 target price on shares of Astrazeneca PLC in a research report on Friday, July 28th. Finally, Morgan Stanley cut shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $34.20.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.